Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress
Go back to Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 51.35 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.35 | 52 Week High | $17.00 | |||
| Open | $51.35 | 52 Week Low | $3.55 | |||
| Day High | $51.35 | P/E | N/A | |||
| Day Low | $51.35 | EPS | $-1.33 | |||
| Volume | 2,096 | |||||
